We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Marketing Home Genomics Tests Should Be Undertaken with Caution

By Labmedica staff writers
Posted on 27 Mar 2008
More than two-dozen companies have been marketing a range of genetic tests directly to consumers concerned about genetic conditions. More...
These conditions include those related to risks for disease, other genetic traits, and ancestry. Some of these companies have marketed "whole genome scans,” which provide assessments of risk for various health conditions ranging from the type of earwax an individual forms to a risk for disease, including cancer, diabetes, and blindness.

According to Dr. Kenneth Offit, M.D., M.P.H., chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), marketing of "at home” genomic tests for disease risk may be premature. "Health professionals are now faced with the prospect of their patients coming to the office, a DNA profile in hand, asking for preventative management tailored to their specific disease risks,” Dr. Offit wrote in the March 19, 2008 special genomics issue of the Journal of the American Medical Association (JAMA).

Dr Offit is concerned about the scientific accuracy of some of these tests, because "they have not yet been validated in forward looking [prospective] clinical studies.” In addition, he wrote, the laboratory accuracy of these tests may vary. A second concern voiced in the commentary is the "direct to consumer” aspect of the marketing of these tests, which excludes guidance from healthcare professionals.

The JAMA article reminds readers that certain state health departments, including New York's, have indicated that genetic testing for disease risk must be requested by a licensed healthcare professional and must be performed in an approved clinical laboratory.

As one of the leaders of the clinical introduction of genetic testing for breast and colon cancer over the past decade, Dr. Offit is in favor of the cautious introduction of new "whole genome” testing, preferably in the setting of ongoing clinical trials. "Those of us in the field of genetic testing for cancer risk proceeded cautiously…The same approach should be followed for genomic testing for other disease risks” he said. "Not doing so runs the risk of dangerously reassuring some and needlessly worrying the already worried [as] well.”


Related Links:
Memorial Sloan-Kettering Cancer Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: (a) CTC separation using contraction-expansion inertial microfluidics. (b) CTC detection using the YOLOv8 deep learning model. (Image Credit: Junyi Ouyang, Haiqin Li)

Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis

Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.